Skip to content

Author

Daniela Quigee

We have 1 of 14 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis

Objective By 2021, regulatory agencies had approved two glucagon-like peptide-1 receptor agonists (GLP-1RAs), semaglutide and liraglutide, for the treatment of type 2 diabetes and obesity. Since then, concerns have emerged about whether adverse events (AEs) differ by GLP-1RA or indication. Research design and methods W...

Samuel A. Fisch, Eitan J. Neugut, Nicole Cornet et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.